Skip to main content

Press Releases

Printer Friendly VersionView printer-friendly version << Back
Seres Therapeutics to Present at Three Upcoming March Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at each of the following upcoming healthcare conferences:

  • Chardan’s Inaugural Microbiome Summit: a corporate overview will be presented on Thursday, March 7th at 8:10 a.m. ET in New York, NY.
  • Cowen and Company 39th Annual Health Care Conference: a corporate overview will be presented on Monday, March 11th at 11:20 a.m. ET in Boston, MA.
  • Oppenheimer 29th Annual Healthcare Conference: a corporate overview will be presented on Tuesday, March 19th at 11:30 a.m. ET in New York, NY.

A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay will become available approximately one hour after each event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ most advanced program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for recurrent C. difficile infection. SER-287 is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. For more information, please visit

Source: Seres Therapeutics, Inc.

IR or PR Contact:
Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467
Vice President, Investor Relations and Corporate Communications

Back to top